nvo novo nordisk news

BNP PARIBAS EXANE Upgrades Novo Nordisk A (NVO)

Fintel reports that on January 5, 2025, BNP PARIBAS EXANE upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Neutral to Outperform. Analyst Price Forecast Suggests 65.56% Upside As of December 23,

ETF Daily News · 6h

Novo Nordisk A/S (NYSE:NVO) Upgraded to Market Perform at Sanford C. Bernstein

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at Sanford C. Bernstein from an “underperform” rating to a “market perform” rating in a research note issued on Monday,

Business Insider · 1d

Novo Nordisk upgraded to Market Perform at Bernstein on valuation

As previously reported, Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform with a price target of DKK 600, up from DKK

Yahoo Finance · 23h

Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet

Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

24/7 Wall St · 20h

Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).

Yahoo Finance3m

Does Novo Nordisk A/S (NVO) Have an Attractive Valuation?

ClearBridge Large Cap Growth Strategy highlighted stocks like Novo Nordisk A/S (NYSE:NVO), in the Q4 2024 investor ...

58mon MSN

Novo Nordisk, Valo Health expand drug discovery deal

Danish drugmaker Novo Nordisk (NVO) (OTCPK:NONOF) and AI-focused biotech Valo Health announced Wednesday an agreement to ...

45m

Novo Nordisk Expands Drug Discovery Collaboration With Valo Health For Cardiometabolic Diseases

Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...

Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...

Better Buy: Novo Nordisk vs. AstraZeneca

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Novo Nordisk: Be Greedy When Others Are Fearful

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Novo Nordisk's Sponsorship Deals With UK Pharmacies Linked To Weight-Loss Drugs Raise Ethical Concerns

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

Morningstar5d

Novo Nordisk AS ADR NVO

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

2don MSN

Is Novo Nordisk an Undervalued Stock to Buy Now?

Novo Nordisk (NYSE: NVO) has sparked investor interest primarily because of its weight loss treatments. Where to invest ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results